Taurine 7 pp 191-198 | Cite as

Taurine Improves Congestive Functions in a Mouse Model of Fragile X Syndrome

  • Abdeslem El Idrissi
  • Latifa Boukarrou
  • Carl Dokin
  • W. Ted Brown
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 643)


Increased seizure susceptibility is a feature of the mouse model for fragile X that has parallels in the hyperarousal and prevalence of seizures in the fragile X syndrome. Our investigation of the basis for the increased seizure susceptibility of the fragile X mouse indicated a reduction in GABAA receptor expression and increased expression of glutamic acid decarboxylase (GAD), the enzyme responsible for GABA synthesis. Taurine-fed mice also show these GABAergic alterations. However, unlike fragile X mice, taurine-fed mice show a significant increase in memory acquisition and retention. This discordance implies that there may be divergent events downstream of the biochemical changes in the GABAergic system in these two mouse models. To investigate the divergence of these two models we fed taurine to fragile X mice. Our preliminary data shows that taurine supplementation to fragile X mice resulted in a significant improvement in acquisition of a passive avoidance task. Since taurine is an agonist for GABAA receptor, we suggest that chronic activation of GABAA receptors and the ensuing alterations in the GABAergic system may have beneficial effects in ameliorating the learning deficits characteristic of the fragile X syndrome.


Passive Avoidance Glutamic Acid Decarboxylase Dark Compartment GABAergic System Passive Avoidance Task 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bakker CE, Verheij C, Willemsen R, van der Helm R, Oerlemans F, Vermeij M, Bygrave A, Hoogeveen AT, Oostra BA, Reyniers E, De Boulle K, D’Hooge R, Cras P, van Velzen D, Nagels G, Marti JJ, De Deyn P, Darby JK, Willems PJ (1994) Fmr1 knockout mice: a model to study fragile X mental retardation. Cell 78:23–33Google Scholar
  2. Chen L, Toth M (2001) Fragile X mice develop sensory hyperreactivity to auditory stimuli Neurosci 103:1043–1050CrossRefGoogle Scholar
  3. del Olmo N, Bustamante, J, del Rio RM, Soli J (2000) Taurine activates GABA(A) but not GABA(B) receptors in rat hippocampal CA1 area. Brain Res 864 298–307PubMedCrossRefGoogle Scholar
  4. El Idrissi A, Ding X-H, Scalia J, Trenkner E, Brown WT, Dobkin C (2005) Decreased GABAA receptor expression in the seizure-prone fragile X mouse. Neurosci Lett 377:141–146PubMedCrossRefGoogle Scholar
  5. El Idrissi A, Trenkner E (2003) Taurine regulates mitochondrial calcium homeostasis. In: Lombardini JB, Schaffer SW, Azuma J (eds) Taurine 5 Beginning the 21st Century, Adv Exp Med Biol, Vol 526, Kluwer Press, NewYork, pp 527-536Google Scholar
  6. El Idrissi A, Trenkner E (2004) Taurine as a modulator of excitatory and inhibitory neurotransmission. Neurochem Res 29:189–197PubMedCrossRefGoogle Scholar
  7. El Idrissi A, Messing J, Scalia J, Trenkner E (2003) Prevention of Epileptic Seizures through taurine. Adv Exp Med Biol 526: 515–525PubMedGoogle Scholar
  8. El Idrissi A, Trenkner E (1999) Growth factors and taurine protect against excitotoxicity by stabilizing calcium homeostasis and energy metabolism. J Neurosci 19:9459–9468PubMedGoogle Scholar
  9. Hagerman RJ (2002) Physical and behavioral phenotype. In: Hagerman RJ, Hagerman PJ (eds) Fragile X syndrome Diagnosis, treatment and research, Johns Hopkins University Press, Baltimore, pp 3–109Google Scholar
  10. Huxtable RJ (1989) Taurine in the central nervous system and the mammalian action actions of taurine. Prog Neurobiol 32:471–533PubMedCrossRefGoogle Scholar
  11. Levinskaya N, Trenkner E, El Idrissi A (2006) A Increased GAD-positive neurons in the cortex of taurine-fed mice. Adv Exp Med Biol 583 411–417PubMedCrossRefGoogle Scholar
  12. Kuriyama K, Hashimoto T (1998) Interrelationship between taurine and GABA. Adv Exp Med Biol 442:329–337PubMedGoogle Scholar
  13. Mellor JR, Gunthorpe MJ, Randall AD (2000) The taurine uptake inhibitor guanidinoethyl sulphonate is an agonist at gamma-aminobutyric acid(A) receptors in cultured murine cerebellar granule cells. Neurosci Lett 286:25–28PubMedCrossRefGoogle Scholar
  14. Musumeci SA, Bosco P, Calabrese G, Bakker C, De Sarro GB, Elia M, Ferri R, Oostra BA (2000) Audiogenic seizures susceptibility in transgenic mice with fragile X syndrome. Epilepsia 41:19–23PubMedCrossRefGoogle Scholar
  15. Quinn MR, Harris CL (1995) Tautine allosterically inhibits binding of [35S]-t-butylbicyclophosphorothionate (TBPS) to rat brain synaptic membranes. Neuropharmacol 34:1607–1613CrossRefGoogle Scholar
  16. Riback CE, Lauterborn JC, Navetta MS, Gall CM (1993) The inferior colliculus of GEPRs contains greater numbers of cells that express glutamate decarboxylase (GAD67) mRNA. Epilepsy Res 14:105–113CrossRefGoogle Scholar
  17. Sturman JA (1993) Taurine in development. Physiol Rev 73:119–147PubMedGoogle Scholar
  18. Wisniewski KE, Segan SM, Miezejeski CM, Sersen EA, Rudelli RD (1991) The Fra(X) syndrome: neurological, electrophysiological, and neuropathological abnormalities. Am J Med Genet 38:476–480PubMedCrossRefGoogle Scholar
  19. Wu JY, Tang XW, Schloss JV, Faiman MD (1998) Regulation of taurine biosynthesis and its physiological significance in the brain. Adv Exp Med Biol 442:339–345PubMedGoogle Scholar
  20. Yan QJ, Asafo-adjei PK, Arnold HM, Brown RE, Bauchwitz RP (2004) A phenotypic and molecular characterization of the fmr1-tm 1 Cgr fragile X mouse. Genes Brain Behav 3:337–359PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Abdeslem El Idrissi
    • 1
  • Latifa Boukarrou
  • Carl Dokin
  • W. Ted Brown
  1. 1.Biology/Neuroscience College of Staten IslandCity University of New York Graduate SchoolNew york

Personalised recommendations